Repligen (RGEN) to Release Earnings on Tuesday

Repligen (NASDAQ:RGEN) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, April 29th. Analysts expect Repligen to post earnings of $0.35 per share and revenue of $163.65 million for the quarter. Repligen has set its FY 2025 guidance at 1.670-1.760 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $144.75 on Friday. The stock has a market capitalization of $8.13 billion, a P/E ratio of -283.82, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $102.97 and a 1-year high of $182.52. The business has a 50-day moving average price of $139.80 and a two-hundred day moving average price of $145.86.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday, April 16th. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, April 17th. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Repligen presently has a consensus rating of “Hold” and an average target price of $176.82.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.